Preoperative Physical Activity Intervention in Patients Before Planned Liver Resection for Cancer (APACHE) (APACHE)

July 18, 2022 updated by: Célia Turco

Preoperative Physical Activity Intervention in Patients Before Planned Liver Resection for Cancer

The aim of this study is to assess the impact of preoperative physical activity on physical capacities of patients undergoing liver resection for primary or secondary liver cancer.

Study Overview

Detailed Description

The purpose of this study is to investigate the effects of a preoperative exercise program in patients with primary or secondary liver cancer undergoing hepatectomy. Preoperative exercise programs have been shown to be effective in other cancer populations, but have been poorly studied in patients with liver cancer. For these patients, it remains unclear what the optimal composition of such programs should be and how they should be delivered. Outcome measures in this study will include preoperative outcomes (oxygen consumption, quality of life, fatigue and physical activity level, anthropometric measures, plasma concentrations of hepatokines) and postoperative outcomes (length of hospital stay and postoperative complications).

After the study is explained and consent obtained, subjects will be tested on a submaximal exercise on cycloergometer with gas exchanges analysis and with pre and post blood test. Then, they will answer various questionnaires assessing physical activity, quality of life and fatigue.

Patients scheduled for liver resection will be randomized to one of two groups. The first group (experimental group) will be subdivided into two groups: interval training 1 and interval training 2, which differentiate themselves by two different intensities.The second group (control group) will receive standard care.

The prehabilitation program will last 6 weeks with 3 sessions per week and will consist in two interval training programs on a cycloergometer with two different intensities.

One month after surgery, peri and postoperative complications will be noted.

Study Type

Interventional

Enrollment (Actual)

8

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Besançon, France, 25000
        • Chirurgie digestive, viscérale et cancérologique

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Men and women aged >18 years old.
  • Patients with primary liver cancer, biliary tract cancer, liver metastasis endorsed in the University Hospital of Besancon
  • No opposition of patients
  • Join a French social security or receiving such a scheme

Exclusion Criteria:

  • Legal incapacity or limited legal capacity
  • Patients being in the disqualification of another study or under the national register of volunteers
  • Patients unlikely to cooperate or anticipated low cooperation
  • Patients with a maximal oxygen consumption above 35 ml/min/kg

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control group
Patients in control group will follow the standard oncologic care. They will perform only 2 sub-maximal exercises.
Experimental: Interval training 1
Patients in experimental group will perform a 6 weeks' physical activity program with 3 sessions per week. Physical activity intervention will consist in 2 different interval training programs on cycloergometer: Interval training 1 and Interval training 2, with a difference in exercise intensities.
Experimental: Interval training 2
Patients in experimental group will perform a 6 weeks' physical activity program with 3 sessions per week. Physical activity intervention will consist in 2 different interval training programs on cycloergometer: Interval training 1 and Interval training 2, with a difference in exercise intensities.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of Oxgen consumption at anaerobic threshold :
Time Frame: 6 weeks
Oxygen consumption at anaerobic threshold will be assessed at baseline and at the end of the 6 weeks' program with a submaximal exercise performed on cycloergometer
6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative complications with the Dindo Clavien classification :
Time Frame: One month after surgery
Postoperative complications will be assessed using the Dindo Clavien classification which consists in a 7 grades classification (I, II, IIIa, IIIb, IVa, IVb and V).
One month after surgery
Intensive care stay :
Time Frame: One month after surgery
Postoperative intensive care stay will be evaluated (number of days).
One month after surgery
Changes of Hepatokines plasmatic concentrations :
Time Frame: Comparison between plasmatic concentrations pre-exercise (day 1), post exercise (day 1) and at 6 weeks
Fetuin A (ng/mL) concentrations will be analyzed.
Comparison between plasmatic concentrations pre-exercise (day 1), post exercise (day 1) and at 6 weeks
Hepatokines plasmatic concentrations :
Time Frame: Comparison between plasmatic concentrations pre-exercise (day 1), post exercise (day 1) and at 6 weeks
Fibroblast Growth Factor 21 (FGF21) (pg/mL) concentrations will be analyzed.
Comparison between plasmatic concentrations pre-exercise (day 1), post exercise (day 1) and at 6 weeks
Changes in Physical activity level :
Time Frame: Comparison between baseline, after the 6 weeks' program
Physical activity level will be measured using the long-form of the International Physical Activity Questionnaire (IPAQ). It consist in a description of the physical activity level by assessing 5 activity domains during the 7 last days. Physical activity level is expressed in Metabolic Equivalent Tasks (METs). It enables to classify patients in 3 categories : low physical activity level, moderate physical activity level and high physical activity level.
Comparison between baseline, after the 6 weeks' program
Changes in Quality of life :
Time Frame: Comparison between baseline, after the 6 weeks' program
Health related quality of life will be measured with the EORTC Quality of Life Questionnaire QLQ-C30 which is a cancer specific questionnaire. It consists in 30 items to measure 15 dimensions of quality of life. It generates a score between 0 and 100. A higher score means a higher quality of life level.
Comparison between baseline, after the 6 weeks' program
Changes in Fatigue :
Time Frame: Comparison between baseline, after the 6 weeks' program
Fatigue will be measured with the Quality of Life Questionnaire QLQ-FA12 which enables to assess cancer related fatigue. It consists in 12 items to measure 5 dimension go health related fatigue. It generates a score between 0 and 100. A higher score means a higher fatigue level.
Comparison between baseline, after the 6 weeks' program

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 27, 2018

Primary Completion (Actual)

March 31, 2020

Study Completion (Actual)

March 31, 2020

Study Registration Dates

First Submitted

April 6, 2018

First Submitted That Met QC Criteria

May 7, 2018

First Posted (Actual)

May 8, 2018

Study Record Updates

Last Update Posted (Actual)

July 19, 2022

Last Update Submitted That Met QC Criteria

July 18, 2022

Last Verified

July 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Primary Liver Cancer

Clinical Trials on Standard Oncologic care

3
Subscribe